We are dedicated to one thing: improving outcomes for cancer patients.
Available Now! CNSide™, a cerebrospinal fluid (CSF) assay addressing unmet needs for patients with metastatic brain cancer involving the CNS.
Biocept is a molecular diagnostics company with commercialized assays for lung, breast, and other carcinomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid (CSF) in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). Using our proprietary CNSide™ assay to analyze and interrogate CSF-TCs and cfDNA for certain biomarkers, physicians can be better informed about the actionable molecular information associated with a patient’s metastatic cancer and develop a personalized cancer treatment plan.
Get in Touch
9955 Mesa Rim Road
San Diego, CA 92121
Customer Service: 888.332.7729
Human Resources: email@example.com